| Previous close | 21.00 |
| Open | 21.00 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 180.00 |
| Expiry date | 2025-03-21 |
| Day's range | 21.00 - 21.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 938 |
Simply Wall St.AbbVie (NYSE:ABBV) Expands Eye Care Portfolio with Ripple Therapeutics Collaboration, Boosts Growth Potential
AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and strategic acquisitions to bolster its pipeline. However, challenges such as declining profit margins and competitive pressures persist. In the discussion that follows, we will explore AbbVie's core strengths, critical weaknesses, growth opportunities, and key threats to provide a comprehensive overview of the company's current business situation.
- Simply Wall St.
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...
ZacksAbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.
© 2024 Yahoo. All rights reserved.